Elucidating the Impact of Bacterial Lipases, Human Serum Albumin, and FASII

Inhibition on the Utilization of Exogenous Fatty Acids by *Staphylococcus aureus*

Emily L. Pruitt,[a] Rutan Zhang,[b] Dylan H. Ross,[b,#] Nathaniel K. Ashford,[c,#] Xi Chen,[d,#] Francis

Alonzo III,[d,#] Matthew F. Bush,[a] Brian J. Werth,[c] Libin Xu,[b,*]

[a] Department of Chemistry, University of Washington, Seattle, Washington, USA

[b] Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA

[c] Department of Pharmacy, University of Washington, Seattle, Washington, USA

[d] Department of Microbiology and Immunology, Loyola University Chicago- Stritch School of

Medicine, Maywood, Illinois, USA

Running Title: Exogenous fatty acids utilization by *S. aureus*

*, Address correspondence to Libin Xu, libinxu@uw.edu.

Present addresses:

[#]Dylan H. Ross, Pacific Northwest National Laboratory, Richland, Washington, USA

[#]Nathaniel K. Ashford, University of Washington School of Medicine, Seattle, Washington,

USA

[#]Francis Alonzo III, Department of Microbiology and Immunology, University of Illinois-

College of Medicine at Chicago, Chicago, Illinois, USA

ABSTRACT

Staphylococcus aureus only synthesizes straight-chain or branched-chain saturated fatty acids (SCFAs or BCFAs) via the type II fatty acid synthesis (FASII) pathway, but as a highly adaptive pathogen, *S. aureus* can also utilize host-derived exogenous fatty acids (eFAs), including SCFAs and unsaturated fatty acids (UFAs). *S. aureus* secretes three lipases, Geh, sal1, and SAUSA300_0641, which could perform the function of releasing fatty acids from host lipids. Once released, the FAs are phosphorylated by the fatty acid kinase, FakA, and incorporated into the bacterial lipids. In this study, we determined the substrate specificity of *S. aureus* secreted lipases, the effect of human serum albumin (HSA) on eFA incorporation, and the effect of FASII inhibitor, AFN-1252, on eFA incorporation using comprehensive lipidomics. When grown with major donors of fatty acids, cholesteryl esters (CEs) and triglycerides (TGs), Geh was found to be the primary lipase responsible for hydrolyzing CEs, but other lipases could compensate for the function of Geh in hydrolyzing TGs. Lipidomics showed that eFAs were incorporated into all major *S. aureus* lipid classes and that fatty acid-containing HSA can serve as a source of eFAs. Furthermore, *S. aureus* grown with UFAs displayed decreased membrane fluidity and increased production of reactive oxygen species (ROS). Exposure to AFN-1252 enhanced UFAs in the bacterial membrane, even without a source of eFAs, indicating a FASII pathway modification. Thus, the incorporation of eFAs alters the *S. aureus* lipidome, membrane fluidity, and ROS formation, which could affect host-pathogen interactions and susceptibility to membrane-targeting antimicrobials.

IMPORTANCE

   Incorporation of host-derived exogenous fatty acids (eFAs), particularly unsaturated fatty acids (UFAs), by *Staphylococcus aureus* could affect the bacterial membrane fluidity and susceptibility to antimicrobials. In this work, we found that Geh is the primary lipase hydrolyzing cholesteryl esters and, to a less extent, triglycerides (TGs) and that human serum albumin (HSA) could serve as a buffer of eFAs, where low levels of HSA facilitate the utilization of eFAs, but high levels of HSA inhibit it. The fact that the FASII inhibitor, AFN-1252, leads to an increase in UFA content even in the absence of eFA suggests that membrane property modulation is part of its mechanism of action. Thus, Geh and/or the FASII system look to be promising targets to enhance *S. aureus* killing in a host environment by restricting eFA utilization or modulating membrane property, respectively.

KEYWORDS

   Staphylococcus aureus, exogenous fatty acid, bacterial lipase, human serum albumin, AFN-1252, lipidomics,

INTRODUCTION

Antibiotic-resistant bacteria pose a major threat to global health, killing more people than HIV/AIDS or malaria (1). Among them, *Staphylococcus aureus* has been deemed one of the most serious threats, infecting the skin, soft tissue, and blood. It causes nearly 120,000 bloodstream infections with 20,000 associated deaths per year in the United States alone (2). *S. aureus* adapts to the host environment by incorporating exogenous fatty acids (eFAs) into its cell membrane, thereby allowing the bacteria to reduce energy consumption from *de novo* fatty acid biosynthesis, bypass the innate immune response, and withstand drug activity (3–11). Elucidating the effects of body fluids on the metabolism of the bacteria is critical to understanding the host-pathogen interaction and evolution of antimicrobial resistance (3, 12–14).

S. aureus only synthesizes straight-chain or branched-chain saturated fatty acids (SCFAs or BCFAs) via the type II fatty acid synthesis pathway (FASII) but can also utilize host-derived SCFA and unsaturated fatty acids (UFAs) or free fatty acids (FFA) (4, 6, 8, 15, 16). In our recent study, lipidomics analysis of *S. aureus* grown in human serum showed that bacteria incorporate UFAs into the bacterial membrane lipids, and cholesteryl esters and triglycerides are the major donors of fatty acid substrates in serum (3). Human serum albumin, an abundant carrier protein in the bloodstream that binds to acidic and lipophilic compounds, has been shown to sequester FFAs to restrict their exploitation by the bacteria (17, 18), but we hypothesize that it may also serve as a reservoir of fatty acids.

To facilitate the incorporation of eFAs into its membrane, *S. aureus* secretes three lipases, *S. aureus* lipase 1 (sal1), glycerol ester hydrolase (Geh), and SAUSA300_0641 (0641 or sal3), to release FFA from lipids found in serum (Figure 1) (4, 5, 15, 19–22). Once FFAs are released by the lipases, they can be taken up by the bacteria, phosphorylated by the fatty acid

kinase (FakA), and incorporated into the bacterial lipids, with or without further elongation via

the FASII pathway (Figure 1) (3–7). When using triglycerides (TGs) as substrates, Geh can

release both short- (4-carbon) and long-chain substrates (16 and 18-carbon), with a preference

for the long-chain fatty acids linoleic acid (18:2) and oleic acid (18:1), whereas sal1 prefers

short-chain fatty acid (4-carbon) substrates (4, 5, 19–21). 0641 was also found to prefer

hydrolyzing short-chain fatty acids (4-carbon or fewer) from triglycerides (22). Several studies

have revealed the importance of these lipases as multifaceted virulence factors in *S. aureus*

infections; however, the substrate specificity of Geh, sal1, and 0641 on cholesterol esters and the

impact of Geh, sal1, or 0641 knockouts on eFA utilization have not been examined previously.

Incorporated serum UFAs can alter lipid packing, affecting the binding of membrane-

targeting antimicrobials, and as an adaptive mechanism to drug exposure, *S. aureus* has been

shown to modify its membrane and cell wall composition (9, 25–28). AFN-1252, a FabI

inhibitor, has been developed as a FASII-targeting antibiotic, but its effect on broad lipidomic

changes has not been well characterized (7). The therapeutic efficacy of AFN-1252 also remains

in debate, as it shows promising treatment for skin and soft-tissue bacterial infections, but FASII

bypassing variants that utilize host-derived eFAs, bring into question its long-term effectiveness

(9–11, 18, 29–31). Although *S. aureus* can uptake eFAs and use them to evade the effects of

FASII inhibitors and antibiotics, UFAs have also long been known to be toxic to the bacteria (4,

32–34). Polyunsaturated fatty acids (PUFAs), such as the abundant mammalian fatty acid

arachidonic acid, can inflict damage on *S. aureus* upon incorporation into its membrane and kill

the pathogen through a lipid peroxidation mechanism (32, 35, 36).

Despite previous work on the effect of exogenous fatty acids on *S. aureus,* several

significant questions remain. First, the substrate specificity of the released lipases toward

cholesterol esters remains unknown. Second, the comprehensive lipidomic changes resulting

from eFA utilization have not been completely elucidated. Third, the role of albumin as a

reservoir for fatty acids and its impact on eFA incorporation efficacy has not yet been

determined. Fourth, the effect of the FASII inhibitor, AFN-1252, on eFA utilization has not yet

been investigated. To answer these questions, we grew *S. aureus* and *geh*, *sal1*, *0641*, or *fakA*

knockout (KO) mutant strains in tryptic soy broth (TSB) supplemented with eFAs under various

conditions and conducted comprehensive lipidomic analyses of these bacteria. We further

characterized the changes in membrane fluidity and formation of reactive oxygen species

resulting from the incorporation of unsaturated eFAs.

We found that a) Geh is the primary lipase responsible for hydrolyzing cholesteryl esters,

and, to a less extent, triglycerides; b) exogenous fatty acids were incorporated into the bacterial

membrane when grown in serum regardless of the lipase knockout; c) human-serum albumin can

serve as a buffer of eFA for *S. aureus*, facilitating the use of eFAs at a low concentration but

inhibiting eFA utilization at high concentrations; d) AFN-1252 leads to an increase of UFAs in

its membrane with or without eFAs; e) incorporation of unsaturated eFAs leads to increased

membrane fluidity during the exponential growth phase; and f) incorporation of unsaturated

eFAs increases reactive oxygen species formation, inhibiting *S. aureus* growth.

RESULTS

***S. aureus* lipase knockouts grown in serum still incorporate UFAs.** *S. aureus* and

geh-, *sal1-*, *0641-*, or *fakA-* knockout mutant strains (Δ*geh*, Δ*sal1*, Δ*0641*, or Δ*fakA*) were grown

in the presence and absence of human serum, and changes in the lipidome were identified

through hydrophilic-interaction liquid chromatography (HILIC) ion mobility-mass spectrometry

(IM-MS) to determine the role of each enzyme in this environment. HILIC first resolves lipid

species on a scale of seconds based on the polarity of the head groups and then by acyl chain

length and degree of unsaturation within the subclass (37–39). Lipid separation is further

increased through ion mobility, a gas-phase separation orthogonal to liquid chromatography

(LC). As described previously, lipid identification is enhanced by using collisional cross section

(CCS) values obtained from the IM-MS analysis (37, 38). Some serum-derived lipids, such as

phosphatidylcholines, phosphatidylethanolamines, and sphingomyelins, are not truly

incorporated into the bacterial membrane (3). Thus, major lipids that are synthesized by *S.*

aureus, diglucosyldiacylglycerols (DGDGs), lysyl-phosphatidylglycerols (LysylPGs),

phosphatidylglycerols (PGs), and cardiolipins (CLs), were examined (39–41).

We determined the total carbon and unsaturation degrees of the lipid acyl side chains for

the major lipid species in the wild type (WT) and Δ*geh*, Δ*sal1*, Δ*0641*, Δ*fakA* mutants (Figure 2).

As seen in the Figure, *S. aureus* grown in TSB-only displayed higher levels of fully saturated

lipid species compared to those grown in human serum for each lipid class. This is not surprising

since without exogenous fatty acids, the bacteria can only synthesize saturated SCFA or BCFA

de novo. Consistent with previous studies, the Δ*fakA* mutant possessed a higher abundance of

long acyl side chains (8). All strains contained DGDG, PG, and LysylPG saturated lipids with 32

to 37 total carbons, with 33 and 35 carbons being the major species across classes in each strain.

Upon further targeted fragmentation experiments using tandem MS (MS/MS) on select DGDG

and PG lipids, no differences in acyl chain composition were observed across the most abundant

lipids of the wild type, Δ*geh*, Δ*sal1*, Δ*0641* and Δ*fakA* strains grown in TSB-only (Supplemental

Data in Excel). C15:0 was consistently identified as the major component of saturated PGs while

C20:0 was the most abundant FA moiety in DGDGs.

When WT *S. aureus* was grown in TSB supplemented with 20% human serum, lipid

profiles of all membrane lipid classes contained elevated levels of UFAs (such as 33:1, 34:1,

35:1, 36:1, 33:2, 34:2, 35:2, and 36:2) that were absent from strains grown in TSB-only (Figure

2). Linoleic acid (C18:2), palmitic acid (C16:0), and oleic acid (C18:1) comprise the majority of

fatty acids found in human serum, along with a slightly lower amount of stearic acid (18:0) and

arachidonic acid (C20:4) (42, 43). MS/MS experiments confirmed C18:1 and C18:2 were the

dominant UFAs utilized by the WT and lipase mutants (Supplemental Data Set 1). Comparable

levels of C20:1 and C20:2 were also observed, suggesting elongation of oleic and linoleic acids

by *S. aureus*. When grown in the presence of serum, PG lipids in the WT and lipase KOs with

odd-numbered total carbons (e.g, 33 and 35) contain C15:0 as the most abundant acyl side chain

while PGs with even-numbered total carbons (e.g., 34 and 36) contain C16:0, instead of C15:0,

as a major fatty acid. This pattern was not seen in the Δ*fakA* mutant, however, indicating the

increase in C16:0, palmitic acid, likely arose from the serum. As expected, the Δ*fakA* mutant

prevented the incorporation of eFAs into the bacterial membrane (Figure 2). This is consistent

with previous reports of *S. aureus* incorporating serum-derived UFAs into the bacterial lipids and

the necessity of FakA to incorporate eFAs into membrane lipids (3, 7, 8). We noted that Δ*fakA*

showed similar intensities to the WT and lipase KOs for PG 32:2, PG 33:2, and LysylPG 33:2

only when grown in TSB-containing human serum. Although individual lipase knockouts did not

completely prevent the incorporation of host-derived UFAs, the Δ*geh* mutant exhibited the least

UFA abundance overall in DGDGs and CLs. However, Δ*0641* also displayed lower UFA levels

than the WT, implying possible overlapping functions exist between the lipases (4, 5). Much

higher levels of saturated lipids, especially lipids with saturated chains 30:0 and 32:0, were

observed in the Δ*fakA* strain grown in serum, which could indicate upregulation of *de novo* fatty

acid synthesis caused by the loss of FakA.

Substrate specificity of *S. aureus* secreted lipases. To further elucidate the overlapping

substrates among the lipases, the WT and Δ*geh*, Δ*sal1*, Δ*0641*, Δ*fakA* mutants were grown in the

presence of cholesteryl esters (CEs) and triglycerides (TGs), the major donors of eFAs in serum

(3). TSB was supplemented with CE and TG standards containing the unsaturated fatty acids

C18:1, C18:2, or C20:4 at a final concentration of 100 μM for each lipid. Comprehensive

lipidomics was conducted in the same way as described above (Figures 3 and S1).

When grown in the presence of CEs, the WT, Δ*sal1*, and Δ*0641* strains displayed similar

eFA incorporation in PG (Figure 3B), DGDG, LysylPG, and CL (Figure S1) lipid species.

Neither the Δ*fakA* nor Δ*geh* strain contained UFAs in any major lipid classes. This suggests that

Geh is the lipase responsible for hydrolyzing cholesteryl esters. Elongation of the supplemented

CE unsaturated fatty acids was observed in the wild type, Δ*sal1*, and Δ*0641* mutants as

evidenced by the presence of C20:1, C20:2, and C22:4 (Supplemental Data in Excel). MS/MS of

DGDG and PG lipid species confirmed the fatty acyl composition of 34:1 and 34:2 to be C14:0

and C20:1 or C20:2, 35:1 and 35:2 contained C15:0 and C20:1 or 20:2, and PG 36:4 contained

C14:0 and C22:4.

In the presence of TGs, the Δ*geh* strain again had the most significant impact on the

incorporation of eFAs (Figure 3C and 3D). However, Δ*geh* did not completely abolish eFA

incorporation within PG and LysylPG lipids. Differences in the fatty acid composition of PG

36:1 and PG 36:2 between the wild-type, Δ*sal1*, Δ*0641* strains and Δ*geh* were identified with

C18:1 being the most abundant acyl side chain in the Δ*geh* strain and C20:1 for Δ*sal1* and Δ*0641*

strains (see Supplemental Data in Excel). Interestingly, increased levels of saturated lipids were

observed in Δ*geh*, indicating an upregulation of *de novo* fatty acid synthesis in this lipase KO.

Overall, this suggests Geh is the major enzyme hydrolyzing the long-chain triglycerides, but

other lipases can also hydrolyze such TGs.

Human serum albumin as a source of eFAs and its effect on eFA incorporation.

Figure 2 showed that eFAs were incorporated into the bacterial membrane when grown in serum,

regardless of the lipase knockout, indicating that there may be sufficient amounts of FFAs in the

serum, so lipases may not be as necessary in this nutrient-rich environment. FFAs in the

bloodstream are typically bound to human serum albumin (HSA), a carrier protein present at

high concentrations (35-50 mg/mL) in human blood (44). Albumin concentrations vary

throughout the body and sites of infection and decrease with increasing age, highlighting the

importance of understanding the effect of HSA on the utilization of serum fatty acids in *S.*

aureus (18, 44–46). Here, the WT and Δ*fakA* strains were grown in the presence and absence of

fatty acid-containing and fatty acid-free HSA.

We found that fatty acid-containing albumin can indeed serve as a source of eFAs,

indicated by the incorporation of UFAs in the WT when grown in the presence of fatty acid-

containing HSA (Figure 4A for PGs and Figure S2 for other lipid classes). However, we note

that most unsaturated lipids observed when grown in the presence of fatty acid-containing HSA

only contain one or two double bonds, much less than those observed when grown in the

presence of eFA standards, indicating the majority of fatty acids carried by HSA are mono-

unsaturated fatty acids (47, 48). As expected, there were no UFAs incorporated into the

membrane lipids with the Δ*fakA* strain or when the WT was grown in the presence of fatty acid-

free HSA.

To determine if albumin aids *S. aureus* with incorporating FFAs into the bacterial

membrane, the WT and Δ*fakA* mutant were grown in media containing FA-free HSA with the

eFA standards: oleic acid (18:1), linoleic acid (18:2), and arachidonic acid (20:4). As seen in

Figures 4A and S2, we found that FA-free HSA at 10 mg/mL significantly enhanced the

incorporation of UFAs as indicated by the higher levels of unsaturated lipids (Figure 4A).

However, concentrations of albumin vary throughout the body, so in a separate experiment, a

range of 20 to 40 mg/mL was used. We found that FA-free HSA proportionately decreased the

incorporation of UFAs as its concentration increased (Figures 4B and S3). As observed with FA-

free HSA at 10 mg/mL, the WT grown with FA-free HSA at both 20 and 30 mg/mL showed

greater levels of PG 33:1 and 33:2 than the WT grown with eFAs only. These results suggest that

HSA could enhance the utilization of eFAs by *S. aureus* at low concentrations but inhibit the

utilization at high concentrations.

Effect of eFAs on membrane fluidity. Antibiotics, such as daptomycin, have been

shown to have increased bactericidal activity against *S. aureus* with incorporated UFAs, which

corresponds to increased membrane fluidity, and decreased daptomycin bactericidal activity

against *S. aureus* with a high percentage of saturated FAs (25). The membrane fluidity of the WT

and Δ*fakA* mutant were assessed at two time points representing the exponential phase (5 hr) and

stationary phase (24 hr) of growth with the fluorescent probe 1,6-diphenyl 1,3,5-hexatriene

(DHP) in the presence and absence of eFA standards or human serum.

As expected, an increase in membrane fluidity was observed at mid-exponential phase in

the WT when grown in the presence of eFAs or serum than without, indicated by a decrease in

polarization value (Figure 5A). Comparatively, Δ*fakA* consistently displayed a significantly more

rigid membrane compared to the WT in eFAs ($P < 0.05$) and in serum ($P < 0.05$). This is

consistent with incorporation of UFAs into the *S. aureus* membrane. However, the Δ*fakA* mutant

also displayed overall increases in membrane fluidity in conditions compared to growth in TSB-

only during mid-exponential phase (Figure 5A). Although UFAs are not incorporated in the

Δ*fakA* mutant, it is possible that the presence of eFAs could lead to a change in endogenous fatty

acid synthesis regulation, including synthesis of BCFA, resulting in a more fluid membrane

overall. In contrast to the mid-exponential phase of growth, no significant differences in fluidity

were found between the WT and Δ*fakA* mutant during the stationary phase (Figure 5B), which

may result from the varied lipid composition with growth phases (8, 53). Little difference was

displayed between strains in TSB only and TSB containing eFA standards, but both strains were

more fluid in the presence of human serum, indicating the impact of the nutritional environment

on responses within the membrane composition.

AFN-1252 enhances UFAs with or without eFA source. An attractive target for drug

discovery is the FASII pathway in *S. aureus*. AFN-1252 is an inhibitor that targets the FabI

enzyme, an enoyl-acyl carrier protein (ACP) reductase that is essential in the final elongation

step of FASII (31, 54, 55). We hypothesized that the FASII inhibitor would enhance the

incorporation of eFAs due to suppression of endogenous FA synthesis. Thus, *S. aureus* was

grown in the presence of AFN-1252, eFAs, or a combination of both. Exposure of *S. aureus* to

AFN-1252 and eFAs resulted in bacterial membrane composed predominantly of UFAs (Figure

6), confirming promotion of eFA incorporation by AFN-1252 (10).

Interestingly, the UFA content in the WT grown with only AFN-1252 in the absence of

eFAs also increased although displaying a different lipid profile from that of eFA only group

(Figure 6 and S4). Upon MS/MS fragmentation, these UFA-containing lipids exhibited different

patterns from those grown in the presence of eFAs, mostly containing fatty acids with one double

bond. As also seen in prior experiments when *S. aureus* is exposed to eFAs, PG 33:1 was found

to be composed of C15:0 (241 *m/z*) and C18:1 (281 *m/z*), but in the presence of AFN-1252 only,

PG 33:1 was found to be composed of C14:0 (227 *m/z*) and C19:1 (295 *m/z*) (Figure 7). This is

not surprising as AFN-1252 inhibits FabI, which reduces a double bond to a saturated carbon-

carbon bond in the FASII cycle, indicating possible accumulation of the ACP intermediate (55).

PG 33:2 in *S. aureus* with AFN-1252 contained C14:1, C19:1 (295 *m/z*), C16:1 (253 *m/z*) and

C17:1 (267 *m/z*), further suggesting accumulations of the unsaturated ACP intermediate (Figure

7B). Such fatty acid compositional changes reveal a different aspect of the mechanism of action

of AFN-1252, which warrants further investigation in the future.

Effect of eFAs on ROS formation. When *S. aureus* was grown with exogenous fatty

acid sources, host-derived fatty acids were incorporated into the membrane, resulting in

increased levels of PUFAs (Figures 2, 3, and 4) and growth inhibition by UFAs (Figure 8A).

PUFAs such as linoleic acid (18:2), a major UFA found in human skin, and arachidonic acid

(20:4), which is released in humans during inflammatory responses, have been shown to be toxic

to the bacteria and kill through lipid peroxidation (35, 36). Reactive oxygen species (ROS),

produced by phagocytes in PUFA-rich environments, also play an integral role in bacterial

killing by oxidative damage (56, 57). To examine the effect of incorporated eFAs on ROS

formation in the bacterial cells, the WT and Δ*fakA* mutant were grown with and without eFA

standards, and ROS production was measured using the fluorogenic dye, H_2DCFDA. We

observed a significant increase of ROS in the WT strain when the measurements were taken in

an eFA-rich environment (Figure 8B). Small increases in ROS formation were also observed in

Δ*fakA* mutant, but not as significant as in the WT strain. This suggests that the incorporation of

PUFAs into the membrane lipids is necessary to increase oxidative stress and enhance their

killing activity.

DISCUSSION

Role of lipases in the utilization of serum lipids by *S. aureus*. Although *S. aureus* is

known to utilize serum lipids and is thought to depend on Geh to incorporate eFAs from

lipoproteins, comprehensive lipidomic studies on the role of bacterial lipases and their substrate

specificity on cholesteryl esters have not yet been performed (3, 4, 20, 58). We found that the

incorporation of fatty acids from cholesteryl esters required Geh, but not Sal1 and 0641 (Figure

2). On the other hand, none of the lipase mutants grown in the presence of TGs showed a

complete lack of UFA incorporation; however, UFAs were decreased in the Δ*geh* mutant

compared to Δ*sal1* and Δ*0641*. This is consistent with previous studies that observed a *geh*

mutant could still incorporate some UFAs into PG lipids in the presence of human low-density

lipoproteins (4). It is likely that Sal1 or 0641 can hydrolyze FAs from TGs to compensate for the

absence of Geh. PUFA-containing lipids were not seen at significant levels, whereas

monounsaturated lipid species were abundant, implying that the 20:4 PUFA is not preferentially

utilized from TGs. Thus, our data suggest that Geh is essential for hydrolyzing UFAs from CEs,

whereas other lipases have overlapping functions to release fatty acids from TGs.

Concentration-dependent effect of human serum albumin on eFA incorporation. We

determined that in addition to serum lipoproteins, human serum albumin can serve as a source of

eFAs for the bacteria, primarily supplying oleic and linoleic acid (Figure 4A). Although a

previous report demonstrated that albumin could sequester exogenous oleic acid from *S. aureus,*

preventing the inactivation of the antibiotic daptomycin, that study used fatty acid-free HSA at

10 mg/L (18). Furthermore, we observed that eFA utilization by *S. aureus* had an inverse

relationship with albumin concentration, where lower HSA levels promoted FFA incorporation

whereas higher levels reduced incorporation. Hypoalbuminemia, diagnosed at albumin levels

<35 mg/mL, has recently been significantly associated with increased risk and adverse outcomes

of deep musculoskeletal *S. aureus* infections (49, 50). Our findings of albumin concentration

affecting eFA incorporation corroborate virulence pathways by which the bacteria utilize host

fatty acids to promote survival during infection and tolerate antibiotic treatments (4, 10, 27).

Although all lipid species displayed an overall decreasing abundance pattern with increasing

albumin concentration, PG 15:0/20:4 levels remained comparatively high at 40 mg/mL, which

may be a result of albumin preferentially binding to monounsaturated fatty acids, therefore

leaving PUFAs such as arachidonic acid (20:4) and linoleic acid (18:2) more readily available.

Cell membrane fluidity changes. As expected from incorporating host-derived fatty

acids into its phospholipids, the membrane fluidity of *S. aureus* increased in eFA-rich

environments (Figure 5). Consistent with previous studies of the Δ*fakA* mutant grown with oleic

acid, Δ*fakA* had a significantly more rigid membrane at the mid-exponential phase than the wild-

type due to its lack of ability to incorporate eFAs (8, 27). On the other hand, the fluidity of Δ*fakA*

strains also increased overall upon eFA and serum treatment (Figure 5A). This provides evidence

that differences in membrane fluidity are not entirely due to eFA incorporation, instead

suggesting that these environments signal for altered endogenous fatty acid metabolism and

composition (8, 61), such as the production of branched-chain fatty acids.

FASII modification and eFA utilization with AFN-1252 exposure. Therapeutic value

of FASII inhibitors remains in debate, as *S. aureus* can bypass suppressed endogenous fatty acid

synthesis by utilizing eFAs (9, 11, 18). Lipidomics of *S. aureus* grown with AFN-1252-only

revealed a significant increase in the proportion of UFAs with abnormally long chains (C19:1)

and phospholipids with various fatty acid combinations (C14:1, C16:1, C17:1, or C19:1),

suggesting accumulation of the acyl-ACP intermediate at the inhibited FabI step (9, 55, 64). In

the presence of eFAs and AFN-1252, the bacteria indeed incorporated more eFAs than eFAs

alone, but the overall UFA content is lower than when treated with AFN-1252 only (Figure 6).

This data indicates *S. aureus* preferably continued to initiate new acyl chains, leading to

intermediate accumulation, rather than completely favor FASII bypass with eFA; however,

preferred pathways and adaptive mechanisms differ based on experimental conditions such as

fatty acid sources or FASII inhibitor concentrations (9, 10, 55, 63, 65). AFN-1252 has

demonstrated promising synergistic effects when combined with daptomycin by blocking decoy

phospholipid release or bacterial growth (18, 65). We speculate that the increased UFA ratio of

S. aureus in the presence of AFN-1252 could also contribute to enhanced daptomycin activity, as

daptomycin targets specific fluid areas of the membrane (15, 25, 66).

To summarize, using comprehensive lipidomics and genetic KOs, this work demonstrated

the importance of various *S. aureus* lipases in the utilization of host-derived CEs and TGs,

identified a surprising role of HSA as a buffer of eFAs, and revealed an underappreciated

biological consequence of the FASII inhibitor AFN-1252, all of which could lead to new

approaches to enhance *S. aureus* killing in a host environment.

MATERIALS AND METHODS

Bacterial strains and growth conditions. Studies were conducted using the USA300 LAC

wild-type (WT) strain of *Staphylococcus aureus*, along with isogenic Δ*geh*, Δ*sal1*, Δ*0641*, and

Δ*fakA* mutants. Δ*geh*, Δ*sal1*, and Δ*0641* mutants were generated as previously described (5). To

generate a Δ*fakA* mutant, five hundred-fifty base pair regions of homology upstream and

downstream of the *fakA* open reading frame (SAUSA300_1119) were amplified from WT *S.*

aureus genomic DNA using primer pairs *fakA*-SOE-1

(CCCGGTACCGGTGATTTAAGCGTAAGTCA) and *fakA*-SOE2

(GGTAGTTTTTTATTTTAAATTTTTCAAGTTGTCCTCCT) or *fakA*-SOE3

(AGGAGGACAACTTGAAAAATTTAAAATAAAAAACTACC) and *fakA*-SOE4

(CCCGAGCTCACCTTTAACAGTTATAGTTTG). The resulting amplicons were used in a

splicing by overlap extension (SOE) PCR along with primer pair *fakA*-SOE-1 and *fakA*-SOE4.

The final amplicon was subcloned into the pIMAY plasmid after digestion with restriction

endonucleases KpnI and SacI (73). Allelic replacement was carried out as previously described

(74). This series of knockouts (KOs) target individual lipases or FakA. Each strain was grown to

stationary phase in triplicate in 1 mL of tryptic soy broth (TSB) at 37°C with shaking for 24

hours in Eppendorf tubes. For human serum treatments, TSB was supplemented with 20% heat-

treated pooled gender human serum (BiolVT; Hicksville, NY). To determine lipase substrate

specificity, the WT and KOs were grown in the presence of pure cholesteryl ester and

triglyceride lipid standards found in serum, containing the fatty acid mix: C18:1, C18:2, and

C20:4 (Nu-Chek Prep, Inc., Elysian, MN) in ethanol each at 100 μM in TSB. To determine the

effect of albumin on eFA sources, the WT and Δ*fakA* mutant were grown with fatty acid-

containing and fatty acid-free HSA (Sigma-Aldrich, St. Louis, MO) at 10-40 mg/mL in TSB. To

determine the effect of AFN-1252 on eFA incorporation and FASII pathway modifications, the

WT was grown in the presence of AFN-1252 (MedChemExpress LLC, Monmouth Junction, NJ)

at 0.025 μM in TSB.

Lipidomics analysis. Cultures were pelleted by centrifugation, washed by resuspension

and centrifugation in phosphate-buffered saline (PBS), and dried in a vacuum concentrator. Total

lipids were extracted by the method of Bligh and Dyer (65). Dried extracts were reconstituted in

2:1 acetonitrile-methanol. Extracts were analyzed by hydrophilic interaction liquid

chromatography (HILIC) coupled with ion mobility-mass spectrometry (IM-MS).

Chromatographic separations were carried out with a Phenomenex Kinetex HILIC column (50 x

2.1 mm, 1.7 μm) on a Waters Acquity FTN UPLC (Waters Corp., Milford, MA) (38). The

solvent system consists of mobile phases (A) 95% acetonitrile/5% water with 5 mM ammonium

acetate and (B) 50% acetonitrile/50% water with 5 mM ammonium acetate. A flow rate of 0.5

mL/min was used with the following linear gradient conditions: 0-0.5 min, 100% A; 2 min, 90%

A; 3.5-4 min, 70% A; and 4.5-6 min, 100% A. Injection volumes were 5 μL for both positive and

negative modes. CCS calibration was created with phosphatidylcholine and

phosphatidylethanolamine CCS standards as previously described (38). IM-MS analysis was

performed on a Waters Synapt XS HDMS (Water Corp., Milford, MA) in both positive and

negative ionization modes as described previously (wave velocity, 500 m/s; wave height, 40 V)

(37, 38). Additional targeted MS/MS experiments were performed with a collision energy ramp

of 30-45 eV to determine FA contents of selected DGDG (positive mode) and PG (negative

mode) lipid species.

Data analysis. Data alignment and peak detection were performed in Progenesis QI

(Nonlinear Dynamics; Waters Corp., Milford MA) with normalization to all compounds.

Retention time calibration and lipid identification were calculated with the Python package,

LiPydomics (66). Multivariate statistics were created through LiPydomics and ClustVis (66, 67).

MS/MS analysis and identification of the most abundant FAs was performed in Skyline utilizing

a targeted lipid library generated with LipidCreator (68, 69).

Cell membrane fluidity assay. The WT and Δ*fakA* mutant strains were grown to mid-

exponential and stationary phase in 5 mL of TSB at 37 °C with shaking in Falcon tubes. Each

strain was grown in the presence and absence of 20% human serum (v/v) or the fatty acid mix:

oleic acid (18:1), linoleic acid (18:2), and arachidonic acid (20:4) (Nu-Chek Prep, Inc., Elysian,

MN), each at a final concentration of 100 μM. Cultures were pelleted by centrifugation, washed,

and resuspended in normal saline at a McFarland reading of 0.9. Cell membrane fluidity was

measured by polarizing spectrofluorometry using a BioTek Synergy H1 plate reader (BioTek

Instruments, Winooski, VT) with the fluorescent probe, 1,6-diphenyl-1,3,5-hexatriene (DPH).

Growth Curves. Overnight cultures of the WT and Δ*fakA* strains were diluted 1:100 in

TSB for growth curve measurements. Cells were added to a Costar 96-well flat-bottom

microplate and grown with FFA standards. Growth was monitored at 600 nm using a BioTek

Synergy H1 plate reader (BioTek Instruments, Winooski, VT) set at 37 °C with continuous,

double orbital shaking.

Reactive oxygen species measurements. The WT and Δ*fakA* mutant strain were grown

to stationary phase in 7 mL of MHB50 at 37 °C with shaking for 24 hours in Falcon tubes. Both

strains were grown in the presence and absence of the fatty acid mix: oleic acid (18:1), linoleic

acid (18:2), and arachidonic acid (20:4) (Nu-Chek Prep, Inc., Elysian, MN), each at a final

concentration of 100 μM. Cultures were pelleted by centrifugation, resuspended in 7 mL MHB50

containing the fluorogenic dye, 2',7'-dichlorodihydrofluorescein diacetate (H_2DCFDA) at a

concentration of 10 μM, and incubated for 45 minutes at 37°C protected from light. Cultures

were pelleted by centrifugation, washed with saline, and resuspended in 7 mL of MHB50. Cells

were added in triplicate to a black Nunc 96-well flat-bottom microplate in the presence or

absence of the fatty acid mix with a final volume of 200 μL. Reactive oxygen species were

measured by fluorescence readings (λ excitation=485 nm, λ emission=535 nm) using a BioTek

Synergy H1 plate reader set at 37 °C for 8 hours.

434 ACKNOWLEDGEMENTS

435 This work was supported by NIH grant R01AI136979 (to LX and BJW). FA acknowledge the

436 support from NIH Grant R01AI120994 and Burroughs Wellcome Fund Investigators in the

437 Pathogenesis of Infectious Disease Award (1019120.01).

439 REFERENCES

1.   Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C,

Bisignano C, Rao P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S,

Haines-Woodhouse G, Kashef Hamadani BH, Kumaran EAP, McManigal B, Agarwal R,

Akech S, Albertson S, Amuasi J, Andrews J, Aravkin A, Ashley E, Bailey F, Baker S,

Basnyat B, Bekker A, Bender R, Bethou A, Bielicki J, Boonkasidecha S, Bukosia J,

Carvalheiro C, Castañeda-Orjuela C, Chansamouth V, Chaurasia S, Chiurchiù S,

Chowdhury F, Cook AJ, Cooper B, Cressey TR, Criollo-Mora E, Cunningham M, Darboe

S, Day NPJ, De Luca M, Dokova K, Dramowski A, Dunachie SJ, Eckmanns T, Eibach D,

Emami A, Feasey N, Fisher-Pearson N, Forrest K, Garrett D, Gastmeier P, Giref AZ, Greer

RC, Gupta V, Haller S, Haselbeck A, Hay SI, Holm M, Hopkins S, Iregbu KC, Jacobs J,

Jarovsky D, Javanmardi F, Khorana M, Kissoon N, Kobeissi E, Kostyanev T, Krapp F,

Krumkamp R, Kumar A, Kyu HH, Lim C, Limmathurotsakul D, Loftus MJ, Lunn M, Ma J,

Mturi N, Munera-Huertas T, Musicha P, Mussi-Pinhata MM, Nakamura T, Nanavati R,

Nangia S, Newton P, Ngoun C, Novotney A, Nwakanma D, Obiero CW, Olivas-Martinez

A, Olliaro P, Ooko E, Ortiz-Brizuela E, Peleg AY, Perrone C, Plakkal N, Ponce-de-Leon A,

Raad M, Ramdin T, Riddell A, Roberts T, Robotham JV, Roca A, Rudd KE, Russell N,

Schnall J, Scott JAG, Shivamallappa M, Sifuentes-Osornio J, Steenkeste N, Stewardson AJ,

Stoeva T, Tasak N, Thaiprakong A, Thwaites G, Turner C, Turner P, van Doorn HR,

Velaphi S, Vongpradith A, Vu H, Walsh T, Waner S, Wangrangsimakul T, Wozniak T,

Zheng P, Sartorius B, Lopez AD, Stergachis A, Moore C, Dolecek C, Naghavi M. 2022.

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The

Lancet 399:629–655.

2. Kourtis AP, Hatfield K, Baggs J, Mu Y, See I, Epson E, Nadle J, Kainer MA, Dumyati G,

Petit S, Ray SM, Emerging Infections Program MRSA author group, Ham D, Capers C,

Ewing H, Coffin N, McDonald LC, Jernigan J, Cardo D. 2019. *Vital Signs:* Epidemiology

and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible *Staphylococcus*

aureus Bloodstream Infections — United States. MMWR Morb Mortal Wkly Rep 68:214–

219.

3. Hines KM, Alvarado G, Chen X, Gatto C, Pokorny A, Alonzo F, Wilkinson BJ, Xu L.

2020. Lipidomic and Ultrastructural Characterization of the Cell Envelope of

Staphylococcus aureus Grown in the Presence of Human Serum. mSphere 5:e00339-20,

/msphere/5/3/mSphere339-20.atom.

4. Delekta PC, Shook JC, Lydic TA, Mulks MH, Hammer ND. 2018. *Staphylococcus aureus*

Utilizes Host-Derived Lipoprotein Particles as Sources of Fatty Acids. J Bacteriol

200:e00728-17, /jb/200/11/e00728-17.atom.

5. Chen X, Alonzo F. 2019. Bacterial lipolysis of immune-activating ligands promotes evasion

of innate defenses. Proc Natl Acad Sci USA 116:3764–3773.

6. Parsons JB, Frank MW, Jackson P, Subramanian C, Rock CO. 2014. Incorporation of

extracellular fatty acids by a fatty acid kinase-dependent pathway in *S taphylococcus*

aureus: Fatty acid metabolism in *S. aureus*. Molecular Microbiology 92:234–245.

7.   Parsons JB, Broussard TC, Bose JL, Rosch JW, Jackson P, Subramanian C, Rock CO.

481   2014. Identification of a two-component fatty acid kinase responsible for host fatty acid

482   incorporation by Staphylococcus aureus. Proceedings of the National Academy of Sciences

483   111:10532–10537.

484   8.   DeMars Z, Singh VK, Bose JL. 2020. Exogenous Fatty Acids Remodel Staphylococcus

485   aureus Lipid Composition through Fatty Acid Kinase. J Bacteriol 202.

486   9.   Morvan C, Halpern D, Kénanian G, Hays C, Anba-Mondoloni J, Brinster S, Kennedy S,

487   Trieu-Cuot P, Poyart C, Lamberet G, Gloux K, Gruss A. 2016. Environmental fatty acids

488   enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted

489   antimicrobials. Nat Commun 7:12944.

490   10.   Kénanian G, Morvan C, Weckel A, Pathania A, Anba-Mondoloni J, Halpern D, Solgadi A,

491   Dupont L, Henry C, Poyart C, Fouet A, Lamberet G, Gloux K, Gruss A. 2019. Permissive

492   Fatty Acid Incorporation in Host Environments Promotes Staphylococcal Adaptation to

493   FASII Antibiotics Cell Rep. 29, 3974-3982.e4.

494   11.   Gloux K, Guillemet M, Soler C, Morvan C, Halpern D, Pourcel C, Vu Thien H, Lamberet

495   G, Gruss A. 2017. Clinical Relevance of Type II Fatty Acid Synthesis Bypass in

496   Staphylococcus aureus. Antimicrob Agents Chemother 61:e02515-16, e02515-16.

497   12.   Garber ED. 1960. The Host As A Growth Medium. Annals of the New York Academy of

498   Sciences 88:1187–1194.

499   13.   Krismer B, Liebeke M, Janek D, Nega M, Rautenberg M, Hornig G, Unger C,

500   Weidenmaier C, Lalk M, Peschel A. 2014. Nutrient Limitation Governs Staphylococcus

501   aureus Metabolism and Niche Adaptation in the Human Nose. PLoS Pathog 10:e1003862.

502   14.   Valentino MD, Foulston L, Sadaka A, Kos VN, Villet RA, Santa Maria J, Lazinski DW,

503   Camilli A, Walker S, Hooper DC, Gilmore MS. 2014. Genes Contributing to

504   Staphylococcus aureus Fitness in Abscess- and Infection-Related Ecologies. mBio 5.

505   15.   Sen S, Sirobhushanam S, Johnson SR, Song Y, Tefft R, Gatto C, Wilkinson BJ. 2016.

506   Growth-Environment Dependent Modulation of Staphylococcus aureus Branched-Chain to

507   Straight-Chain Fatty Acid Ratio and Incorporation of Unsaturated Fatty Acids. PLoS ONE

508   11:e0165300.

509   16.   Altenbern RA. 1977. Cerulenin-Inhibited Cells of *Staphylococcus aureus* Resume Growth

510   When Supplemented with Either a Saturated or an Unsaturated Fatty Acid. Antimicrob

511   Agents Chemother 11:574–576.

512   17.   van der Vusse GJ. 2009. Albumin as Fatty Acid Transporter. Drug Metabolism and

513   Pharmacokinetics 24:300–307.

514   18.   Pee CJE, Pader V, Ledger EVK, Edwards AM. 2019. A FASII Inhibitor Prevents

515   Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production.

516   Antimicrob Agents Chemother 63:e02105-18, /aac/63/4/AAC.02105-18.atom.

517   19.   Rollof J, Hedström SA, Nilsson-Ehle P. 1987. Purification and characterization of a lipase

518   from Staphylococcus aureus. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid

519   Metabolism 921:364–369.

520   20.   Cadieux B, Vijayakumaran V, Bernards MA, McGavin MJ, Heinrichs DE. 2014. Role of

521   Lipase from Community-Associated Methicillin-Resistant Staphylococcus aureus Strain

522   USA300 in Hydrolyzing Triglycerides into Growth-Inhibitory Free Fatty Acids. J Bacteriol

523   196:4044–4056.

21.   Simons J-WFA, Adams H, Cox RC, Dekker N, Gotz F, Slotboom AJ, Verheij HM. 1996.

The Lipase from Staphylococcus aureus. Expression in Escherichia coli, Large-scale

Purification and Comparison of Substrate Specificity to Staphylococcus hyicus Lipase. Eur

J Biochem 242:760–769.

22.   Kumar NG, Contaifer D, Wijesinghe DS, Jefferson KK. 2021. Staphylococcus aureus

Lipase 3 (SAL3) is a surface-associated lipase that hydrolyzes short chain fatty acids. PLoS

ONE 16:e0258106.

23.   Hu C, Xiong N, Zhang Y, Rayner S, Chen S. 2012. Functional characterization of lipase in

the pathogenesis of Staphylococcus aureus. Biochemical and Biophysical Research

Communications 419:617–620.

24.   Nguyen M-T, Luqman A, Bitschar K, Hertlein T, Dick J, Ohlsen K, Bröker B, Schittek B,

Götz F. 2018. Staphylococcal (phospho)lipases promote biofilm formation and host cell

invasion. International Journal of Medical Microbiology 308:653–663.

25.   Boudjemaa R, Cabriel C, Dubois-Brissonnet F, Bourg N, Dupuis G, Gruss A, Lévêque-Fort

S, Briandet R, Fontaine-Aupart M-P, Steenkeste K. 2018. Impact of Bacterial Membrane

Fatty Acid Composition on the Failure of Daptomycin To Kill *Staphylococcus aureus*.

Antimicrob Agents Chemother 62:e00023-18, /aac/62/7/e00023-18.atom.

26.   Nishi H, Komatsuzawa H, Fujiwara T, McCallum N, Sugai M. 2004. Reduced Content of

Lysyl-Phosphatidylglycerol in the Cytoplasmic Membrane Affects Susceptibility to

Moenomycin, as Well as Vancomycin, Gentamicin, and Antimicrobial Peptides, in

Staphylococcus aureus. Antimicrob Agents Chemother 48:4800–4807.

27.   Lopez MS, Tan IS, Yan D, Kang J, McCreary M, Modrusan Z, Austin CD, Xu M, Brown

EJ. 2017. Host-derived fatty acids activate type VII secretion in *Staphylococcus aureus*.

Proc Natl Acad Sci USA 114:11223–11228.

28.   Mishra NN, Rubio A, Nast CC, Bayer AS. 2012. Differential Adaptations of Methicillin-

Resistant *Staphylococcus aureus* to Serial *In Vitro* Passage in Daptomycin: Evolution of

Daptomycin Resistance and Role of Membrane Carotenoid Content and Fluidity.

International Journal of Microbiology 2012:1–6.

29.   Hafkin B, Kaplan N, Murphy B. 2016. Efficacy and Safety of AFN-1252, the First

Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and

Skin Structure Infections, Including Those in Patients with Significant Comorbidities.

Antimicrob Agents Chemother 60:1695–1701.

30.   Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2009. Type II fatty acid

synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458:83–86.

31.   Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A. 2010.

Essentiality of FASII pathway for Staphylococcus aureus. Nature 463:E3–E3.

32.   Krute CN, Ridder MJ, Seawell NA, Bose JL. 2019. Inactivation of the exogenous fatty acid

utilization pathway leads to increased resistance to unsaturated fatty acids in

Staphylococcus aureus. Microbiology 165:197–207.

33.   Chamberlain NR, Mehrtens BG, Xiong Z, Kapral FA, Boardman JL, Rearick JI. 1991.

Correlation of carotenoid production, decreased membrane fluidity, and resistance to oleic

acid killing in Staphylococcus aureus 18Z. Infect Immun 59:4332–4337.

34.   Greenway DLA, Dyke KGH. 1979. Mechanism of the Inhibitory Action of Linoleic Acid

on the Growth of Staphylococcus aureus. Journal of General Microbiology 115:233–245.

35. Knapp HR, Melly MA. 1986. Bactericidal Effects of Polyunsaturated Fatty Acids. Journal

of Infectious Diseases 154:84–94.

36. Beavers WN, Monteith AJ, Amarnath V, Mernaugh RL, Roberts LJ, Chazin WJ, Davies

SS, Skaar EP. 2019. Arachidonic Acid Kills Staphylococcus aureus through a Lipid

Peroxidation Mechanism. mBio 10, e01333-19.

37. Li A, Hines KM, Xu L. 2020. Lipidomics by HILIC-Ion Mobility-Mass Spectrometry, p.

119–132. *In* Paglia, G, Astarita, G (eds.), Ion Mobility-Mass Spectrometry. Humana, New

York, NY.

38. Hines KM, Herron J, Xu L. 2017. Assessment of altered lipid homeostasis by HILIC-ion

mobility-mass spectrometry-based lipidomics. Journal of Lipid Research 58:809–819.

39. Hines KM, Waalkes A, Penewit K, Holmes EA, Salipante SJ, Werth BJ, Xu L. 2017.

Characterization of the Mechanisms of Daptomycin Resistance among Gram-Positive

Bacterial Pathogens by Multidimensional Lipidomics. mSphere 2:mSphere.00492-17,

e00492-17.

40. Ratledge C, Wilkinson SG (ed). 1988. Microbial Lipids. Academic Press, London, United

Kingdom.

41. Kuhn S, Slavetinsky CJ, Peschel A. 2015. Synthesis and function of phospholipids in

Staphylococcus aureus. International Journal of Medical Microbiology 305:196–202.

42. Brenna JT, Plourde M, Stark KD, Jones PJ, Lin Y-H. 2018. Best practices for the design,

laboratory analysis, and reporting of trials involving fatty acids. The American Journal of

Clinical Nutrition 108:211–227.

43. Buchanan CDC, Lust CAC, Burns JL, Hillyer LM, Martin SA, Wittert GA, Ma DWL.

2021. Analysis of major fatty acids from matched plasma and serum samples reveals highly

comparable absolute and relative levels. Prostaglandins, Leukotrienes and Essential Fatty

Acids 168:102268.

44. Peters, Jr T. 1995. All About Albumin: Biochemistry, genetics, and Medical Applications.

Academic Press, San Diego, CA. https://doi.org/10.1016/B978-0-12-552110-9.X5000-4.

45. Weaving G, Batstone GF, Jones RG. 2016. Age and sex variation in serum albumin

concentration: an observational study. Ann Clin Biochem 53:106–111.

46. Cojutti PG, Candoni A, Ramos-Martin V, Lazzarotto D, Zannier ME, Fanin R, Hope W,

Pea F. 2017. Population pharmacokinetics and dosing considerations for the use of

daptomycin in adult patients with haematological malignancies. Journal of Antimicrobial

Chemotherapy 72:2342–2350.

47. Saifer A, Goldman L. 1961. The free fatty acids bound to human serum albumin. Journal of

Lipid Research 2:268–270.

48. Petitpas I, Grüne T, Bhattacharya AA, Curry S. 2001. Crystal structures of human serum

albumin complexed with monounsaturated and polyunsaturated fatty acids. Journal of

Molecular Biology 314:955–960.

49. Campbell MP, Mott MD, Owen JR, Reznicek JE, Beck CA, Muthukrishnan G, Golladay

GJ, Kates SL. 2022. Low albumin level is more strongly associated with adverse outcomes

and *Staphylococcus aureus* infection than hemoglobin A1C or smoking tobacco. Journal

Orthopaedic Research jor.25282.

50. Wiedermann CJ. 2021. Hypoalbuminemia as Surrogate and Culprit of Infections. IJMS

22:4496.

51.   Zhang T, Muraih JK, Tishbi N, Herskowitz J, Victor RL, Silverman J, Uwumarenogie S,

Taylor SD, Palmer M, Mintzer E. 2014. Cardiolipin Prevents Membrane Translocation and

Permeabilization by Daptomycin. Journal of Biological Chemistry 289:11584–11591.

52.   Jiang J-H, Bhuiyan MS, Shen H-H, Cameron DR, Rupasinghe TWT, Wu C-M, Le Brun

AP, Kostoulias X, Domene C, Fulcher AJ, McConville MJ, Howden BP, Lieschke GJ,

Peleg AY. 2019. Antibiotic resistance and host immune evasion in *Staphylococcus aureus*

mediated by a metabolic adaptation. Proc Natl Acad Sci USA 116:3722–3727.

53.   Koprivnjak T, Zhang D, Ernst CM, Peschel A, Nauseef WM, Weiss JP. 2011.

Characterization of Staphylococcus aureus Cardiolipin Synthases 1 and 2 and Their

Contribution to Accumulation of Cardiolipin in Stationary Phase and within Phagocytes. J

Bacteriol 193:4134–4142.

54.   Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan

N, Rock CO. 2013. Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-

Acyl Carrier Protein Reductase Inhibitor AFN-1252. Antimicrob Agents Chemother

57:2182–2190.

55.   Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. 2011. Metabolic basis for

the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.

Proc Natl Acad Sci USA 108:15378–15383.

56.   Abuaita BH, Schultz TL, O'Riordan MX. 2018. Mitochondria-Derived Vesicles Deliver

Antimicrobial Reactive Oxygen Species to Control Phagosome-Localized Staphylococcus

aureus. Cell Host & Microbe 24:625-636.e5.

57.   Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, Takahashi N, Chan CTY,

Lobritz MA, Braff D, Schwarz EG, Ye JD, Pati M, Vercruysse M, Ralifo PS, Allison KR,

Khalil AS, Ting AY, Walker GC, Collins JJ. 2014. Antibiotics induce redox-related

physiological alterations as part of their lethality. Proc Natl Acad Sci USA 111.

58. Teoh WP, Chen X, Laczkovich I, Alonzo F. 2021. *Staphylococcus aureus* adapts to the host

nutritional landscape to overcome tissue-specific branched-chain fatty acid requirement.

Proc Natl Acad Sci USA 118:e2022720118.

59. Chen X, Teoh WP, Stock MR, Resko ZJ, Alonzo F. 2021. Branched chain fatty acid

synthesis drives tissue-specific innate immune response and infection dynamics of

Staphylococcus aureus. PLoS Pathog 17:e1009930.

60. Kengmo Tchoupa A, Peschel A. 2020. Staphylococcus aureus Releases Proinflammatory

Membrane Vesicles To Resist Antimicrobial Fatty Acids. mSphere 5:e00804-20.

61. DeMars Z, Bose JL. 2018. Redirection of Metabolism in Response to Fatty Acid Kinase in

Staphylococcus aureus. J Bacteriol 200.

62. Ledger EVK, Mesnage S, Edwards AM. 2022. Human serum triggers antibiotic tolerance in

Staphylococcus aureus. Nat Commun 13:2041.

63. Frank MW, Yao J, Batte JL, Gullett JM, Subramanian C, Rosch JW, Rock CO. 2020. Host

Fatty Acid Utilization by Staphylococcus aureus at the Infection Site. mBio 11:e00920-20.

64. Parsons JB, Yao J, Jackson P, Frank M, Rock CO. 2013. Phosphatidylglycerol homeostasis

in glycerol-phosphate auxotrophs of Staphylococcus aureus. BMC Microbiol 13:260.

65. Pathania A, Anba-Mondoloni J, Gominet M, Halpern D, Dairou J, Dupont L, Lamberet G,

Trieu-Cuot P, Gloux K, Gruss A. 2021. (p)ppGpp/GTP and Malonyl-CoA Modulate

Staphylococcus aureus Adaptation to FASII Antibiotics and Provide a Basis for Synergistic

Bi-Therapy. mBio 12:e03193-20.

66.   Müller A, Wenzel M, Strahl H, Grein F, Saaki TNV, Kohl B, Siersma T, Bandow JE, Sahl

658   H-G, Schneider T, Hamoen LW. 2016. Daptomycin inhibits cell envelope synthesis by

659   interfering with fluid membrane microdomains. Proc Natl Acad Sci USA 113:E7077–

660   E7086.

661   67.   Tchoupa AK, Watkins KE, Jones RA, Kuroki A, Alam MT, Perrier S, Chen Y,

662   Unnikrishnan M. 2019. The type VII secretion system protects *Staphylococcus aureus*

663   against antimicrobial host fatty acids. preprint. Microbiology.

664   68.   Bligh EG, Dyer WJ. A RAPID METHOD OF TOTAL LIPID EXTRACTION AND

665   PURIFICATION 7.

666   69.   Ross DH, Cho JH, Zhang R, Hines KM, Xu L. 2020. LiPydomics: A Python Package for

667   Comprehensive Prediction of Lipid Collision Cross Sections and Retention Times and

668   Analysis of Ion Mobility-Mass Spectrometry-Based Lipidomics Data. Anal Chem

669   92:14967–14975.

670   70.   Metsalu T, Vilo J. 2015. ClustVis: a web tool for visualizing clustering of multivariate data

671   using Principal Component Analysis and heatmap. Nucleic Acids Res 43:W566–W570.

672   71.   Adams KJ, Pratt B, Bose N, Dubois LG, St. John-Williams L, Perrott KM, Ky K, Kapahi P,

673   Sharma V, MacCoss MJ, Moseley MA, Colton CA, MacLean BX, Schilling B, Thompson

674   JW, Alzheimer's Disease Metabolomics Consortium. 2020. Skyline for Small Molecules: A

675   Unifying Software Package for Quantitative Metabolomics. J Proteome Res 19:1447–1458.

676   72.   Peng B, Kopczynski D, Pratt BS, Ejsing CS, Burla B, Hermansson M, Benke PI, Tan SH,

677   Chan MY, Torta F, Schwudke D, Meckelmann SW, Coman C, Schmitz OJ, MacLean B,

678   Manke M-C, Borst O, Wenk MR, Hoffmann N, Ahrends R. 2020. LipidCreator workbench

679   to probe the lipidomic landscape. Nat Commun 11:2057.

73. Monk, I. R., Shah, I. M., Xu, M., Tan, M. W. & Foster, T. J. 2012. Transforming the

Untransformable: Application of Direct Transformation To Manipulate Genetically

Staphylococcus aureus and Staphylococcus epidermidis. *mBio* **3**, e00277-11.

74. Grayczyk, J. P., Harvey, C. J., Laczkovich, I. & Alonzo, F. A 2017. Lipoylated Metabolic

Protein Released by Staphylococcus aureus Suppresses Macrophage Activation. *Cell Host*

and Microbe **22**, 678-687.e9.

688
689
690

    FIGURES AND FIGURE LEGENDS

707   **Figure 1.** Schematic showing the release and utilization of exogenous fatty acids by *S. aureus*.

709   **Figure 2.** Relative abundances of lipids of WT (USA300 LAC) and *geh-*, *sal1-*, *0641-*, or *fakA-*

710   knockout mutant strains grown in TSB or TSB + 20% human serum. DGDG:

711   diglucosyldiacylglycerol; PG: phosphatidylglycerol; LysylPG: lysyl-phosphatidylglycerol; CL:

712   cardiolipin. Results are row-centered and scaled by unit variance scaling. N = 4 per group.

Figure 3. Relative abundance of lipids of WT (USA300 LAC) and *geh-*, *sal1-*, *0641-*, or *fakA-*

knockout mutant strains grown in the presence of cholesteryl esters or triglycerides containing

C18:1, C18:2, or C20:4 at 100 µM for each lipid. (A) and (B): saturated and unsaturated lipids in

the strains grown in the presence of cholesteryl esters, respectively. (C) and (D): saturated and

unsaturated lipids in the strains grown in the presence of triglycerides. (E) and (F): MS/MS

fragmentation spectra of two unsaturated PGs. N = 4.

Figure 4. Effect of human serum albumin (HSA) on the incorporation of exogenous fatty acids (eFAs) to WT and *fakA*-knockout strains. (A) Effect of fatty acid-containing HSA and fatty acid-free (FA-F) HSA on the incorporation of eFAs mixture (oleic acid 18:1, linoleic acid 18:2, and arachidonic acid 20:4). (B) The effect of increasing concentrations of FA-F HSA on the incorporation of eFAs. N = 4.

Figure 5. Membrane fluidity of WT and *fakA*-KO (Δ*fakA*) strains grown to the mid-exponential

phase (A) or stationary phase (B) in the presence of eFA standards (18:1, 18:2, and 20:4) or 20%

human serum. N = 4.

Figure 6. Effect of AFN-1252 on the incorporation of eFA standards containing fatty acids 18:1,

18:2, and 20:4. (A) Comparison of the sum of all saturated and unsaturated lipids; (B)

comparison of individual PGs under various conditions. N = 3-4.

Figure 7. Fatty acid composition of PG 33:1 informed by MS/MS fragmentation of the parent

[M+H]⁻ ion from WT grown in the presence of (A) eFA only, (B) AFN-1252 only, or (C) AFN-

1252+eFA.

Figure 8. (A) Growth curve and (B) formation of reactive oxygen species in WT and fakA-KO

strains in the absence or presence of the eFA standard mixture containing fatty acids 18:1, 18:2,

and 20:4.